30 closest matches · ranked by relevance
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in 1-hour Morning Post-dose Dose Forced Expiratory Volume in 1 Second (FEV1) of AB/FF 400/12 μg Compared to AB 400 μg at Week 24 — 0.253; 0.169…
Healthy
Primary: Number of Patients With Treatment-emergent Adverse Events (TEAEs), by Treatment (Safety Analysis Set) — 2; 2; 5; 2 subjects
Glabellar Frown Lines
Primary: Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject — 67.5; 1.2 percentage of…
Invasive Aspergillosis
Primary: Number of Subjects With Adverse Events — 1; 1; 1; 1 participants
Advanced Dupuytren's Disease
Primary: Reduction in Contracture to 5° or Less — 41.9 Percentage of joints
Healthy
Primary: Percentage of Participants With Drug Related Adverse Events — 0.0; 0.0; 0.0; 0.0 Percentage of participants
Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 28 — -0.96; -0.22 Percentage of HbA1c — p=<0.001
Glabellar Frown Lines
Primary: The Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 Year — 235 Participants
Glabellar Frown Lines
Primary: Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject — 70.4; 1.3 percentage of…
Duchenne Muscular Dystrophy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 4; 5; 3; 3 Participants
Chronic Obstructive Pulmonary Disease
Primary: Aggregated Pathology Score — 7.88; 8.15 Score on a scale
Gastrointestinal Cancer · Biliary Tract Cancer
Primary: Part 1: Establish the Maximum Tolerated Dose (MTD) — 100 mg
Diabetic Foot Infections
Primary: Number of Participants With Treatment-related Treatment-emergent Adverse Events as Graded According to the Common Terminology Criteria for Adverse Events v4.02 (CTCAE)…
Diabetic Macular Edema
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) — 3.7; 9.2; 4.3; 7.7 ETDRS letters
Human Immunodeficiency Virus
Primary: Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) — -1.38; -1.40; -0.80 HIV-1 RNA copies/mL
Diabetes Mellitus, Type 2
Primary: Change in Endogenous Glucose Production (EGP) — 2.45; 2.56; 1.95; 2.4 mg/kg*min
Early Course Schizophrenia Spectrum Disorder
Primary: Neural Activity Across Brain Regions During a Spatial Working Memory (sWM) Task- Condition 2 — -0.076; -0.090; -0.072; -0.136 percentage signal change
Idiopathic Pulmonary Fibrosis
Primary: Safety and Tolerability Primarily Assessed by the Number of Patients With Adverse Events — 8; 7; 2; 1 Patients
Diabetic Macular Edema · Diabetic Retinopathy
Primary: Time to Worsening of DME Disease Activity in the Study Eye. — 82.1; 96.1; 19.1 Weeks
Ornithine Transcarbamylase (OTC) Deficiency
Primary: Number of Participants With Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and TEAEs Leading to Discontinuation…
Drug Toxicity
Primary: Percentage of Participants Experiencing Drug-related Serious Adverse Events. — 0; 0; 0; 0 percentage of participants
Leukemia · Myelodysplastic Syndromes · Blastic Plasmacytoid Dendritic Cell Neoplasm
Primary: Overall Response Rate (CR+PR+SD): Percentage of Participants Experiencing Response — 81.8 percentage of participants
Duchenne Muscular Dystrophy
Primary: Number of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) In Participants With Duchenne Muscular Dystrophy — 3; 5 Participants
Neoplasms
Primary: Maximum Tolerated Dose (MTD) of Xentuzumab in Japanese Patients With Advanced Solid Tumours, as Identified by the Number of Patients With Dose-limiting Toxicities (DLTs)…
Safety Issues
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 0; 0; 2; 1 Participants
Duchenne Muscular Dystrophy
Primary: Increase in Dystrophin Expression in the Muscle Biopsies by Immunofluorescence Analyses of Cross-sections and by Western Blot Analyses of Total Protein Extracts — 1; 1…
Dupuytren's Contracture
Primary: Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection — 64; 6.8 Percentage of Joints — p=<0.001
Duchenne Muscular Dystrophy Cardiomyopathy · Cardiomyopathy, Dilated
Primary: Incidence of Treatment-Emergent Adverse Events — 14; 9; 10 Participants
Agitation,Psychomotor · Dementia
Primary: Mean Change From Baseline in Positive and Negative Syndrome Scale-Excited Component (PEC) Total Score — -5.4; -7.1; -2.9; -6.8 score on a scale — p=0.0813
Healthy
Primary: Number of Participants With Drug-related Adverse Events — 0; 0; 0 Participants